Designer drugs: How dangerous are they?

Journal of Neural Transmission, Supplement

Volumn , Issue 66, 2003, Pages 61-83

  Reneman, L ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; NEUROTOXIN; DESIGNER DRUG; SEROTONIN;

AMNESIA; BEHAVIOR; BRAIN REGION; CONFERENCE PAPER; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG ABUSE; DRUG SAFETY; HEALTH HAZARD; HUMAN; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RISK ASSESSMENT; SEROTONINERGIC NERVE CELL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BRAIN; DIAGNOSTIC IMAGING; DRUG EFFECT; METABOLISM; METHODOLOGY; NERVE CELL; REVIEW;

ANIMALS; BRAIN; DESIGNER DRUGS; DIAGNOSTIC IMAGING; HUMANS; NEURONS; SEROTONIN;

EID: 0642338082     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0541-2_4     Document Type: Conference Paper

References (94)

1. Ahmad K (2002) Increased use of amphetamine-type stimulants threatens east Asian countries. Lancet 359:1927
2. Backstrom I, Bergstrom M, Marcusson J (1989) High affinity [3H] paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res 486: 261-268
3. Bakhit C, Morgan ME, Peat MA, Gibb JW (1981) Long-term effects of methamphetamine on the synthesis and metabolism of 5-hydroxytryptamine in various regions of the rat brain. Neuropharmacology 20: 1135-1140
4. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 242: 911-916
5. Battaglia G, Yeh SY, De Souza EB (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29: 269-274
6. 125I]RTI-55: a potent ligand for dopamine transporters. Eur J Pharmacol 194: 133-134
7. Boja JW, McNeill RM, Lewin AH, Abraham P, Carroll FI, Kuhar MJ (1992) Selective dopamine transporter inhibition by cocaine analogs. Neuroreport 3: 984-986
8. Cass WA, Manning MW (1999) Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J Neurosci 19: 7653-7660
9. 1H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. J Magn Reson Imaging 10: 521-526
10. Commins DL, Seiden LS (1986) alpha-Methyltyrosine blocks methylamphetamine-induced degeneration in the rat somatosensory cortex. Brain Res 365: 15-20
11. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden, LS (1987) Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345
12. Curran HV (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evdience and of methodological problems in research. Neuropsychobiology 42: 34-41
13. EMCDDA (2001) Annual report on the state of the drugs problem in the European Union. http://annualreport.emcdda.org/multimedia/Annual_Report_2001/ ar01_en.pdf
14. Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: a 1H MRS study. Neurology 54: 1344-1349
15. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse 16: 93-103
16. Friedman SD, Castaneda E, Hodge GK (1998) Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 61: 35-44
17. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF (1993) Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 34: 423-431
18. Gibb JW, Stone DM, Stahl DC, Hanson GR (1987) The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain. NIDA Res Monogr 76: 316-321
19. Gijsman HJ, Verkes RJ, van Gerven JMA, Cohen AF (1999) MDMA study. Neuropsychopharmacology 21: 597
20. 3H]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain. Neuropsychopharmacology 14: 309-323
21. Harvey DC, Lacan G, Tanious SP, Melega WP (2000) Recovery from methamphetamine induced long-term nigrostriatal dopaminergic deficits without substantia nigra cell loss. Brain Res 871: 259-270
22. Hatzidimitriou G, McCann UD, Ricaurte GA (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 19: 5096-5107
23. Hegadoren KM, Baker GB, Bourin M (1999) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23: 539-553
24. Higuchi T, Graham SH, Fernandez EJ, Rooney WD, Gaspary HL, Weiner MW, Maudsley AA (1997) Effects of severe global ischemia on N-acetylaspartate and other metabolites in the rat brain. Magn Reson Med 37: 851-857
25. Howe FA, Maxwell RJ, Saunders DE, Brown MM, Griffiths JR (1993) Proton spectroscopy in vivo. Magn Reson Q 9: 31-59
26. Huang X, Marona-Lewicka D, Nichols DE (1992) p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent. Eur J Pharmacol 229: 31-38
27. 3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132: 269-276
28. Johnston LD, O'Malley PM, Bachman JG (2002) Monitoring the future national results on adolescent drug use: overview of key findings, 2001. National Institute of Drug Abuse, Bethesda, MD (NIH Pub. No. 02-5105)
29. Kamien JB, Johanson CE, Schuster CR, Woolverton WL (1986) The effects of (+/-)-methylenedioxymethamphetamine and (+/-)-methylenedioxyamphetamine in monkeys trained to discriminate (+)-amphetamine from saline. Drug Alcohol Depend 18: 139-147
30. Kieven MS, Seiden LS (1992) Methamphetamine-induced neurotoxicity: structure activity relationships. Ann NY Acad Sci 654: 292-301
31. Kish SJ (2002) How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? Pharmacol Biochem Behav 71: 845-855
32. Koda LY, Gibb JW (1973) Adrenal and striatal tyrosine hydroxylase activity after methamphetamine. J Pharmacol Exp Ther 185: 42-48
33. Kuikka JT, Tiihonen J, Bergstrom KA, Karhu J, Hartikainen P, Viinamaki H, Lansimies E, Lehtonen J, Hakola P (1995) Imaging of serotonin and dopamine transporters in the living human brain. Eur J Nucl Med 22: 346-350
34. 123I]β-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 13: 295-309
35. Lew R, Sabol KE, Chou C, Vosmer GL, Richards J, Seiden LS (1996) Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period, part II. Radioligand binding and autoradiography studies. J Pharmacol Exp Ther 276: 855-865
36. 18F]fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse 22: 63-69
37. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME (1997) Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766: 113-120
38. McCann UD, Ricaurte GA (2001) Caveat emptor: editors beware. Neuropsychopharmacology 24: 333-334
39. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998a) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurones in human beings. Lancet 352: 1433-1437
40. 11C]WIN-35,428. J Neurosci 18: 8417-8422
41. McKenna DJ, Guan XM, Shulgin AT (1991) 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine. Pharmacol Biochem Behav 38: 505-512
42. Molliver ME, Berger UV, Mamounas LA, Molliver DC, O'Hearn E, Wilson, MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600: 649-661
43. Mordenti J, Chappell (1989) The use of interspecies scaling in toxicokinetics. In: Yacobi A, Kelly J, Batra V (eds) Toxicokinetics and new drug development. Pergamon Press, New York, pp 42-96
44. 1H-MRSI in ecstasy users. Eur Arch Psychiatry Clin Neurosci 251: 114-116
45. O'Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788-2803
46. Parrott AC (2000) Human research on MDMA (3,4- methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 42: 17-24
47. 11C]McN 5652. J Nucl Med 41: 1465-1477
48. 123I-β-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 41: 36-44
49. Pope HG Jr, Ionescu-Pioggia M, Pope KW (2001) Drug use and life style among college undergraduates: a 30-year longitudinal study. Am J Psychiatry 158: 1519-1521
50. Reneman L, Booij J, Schmand B, van den Brink W, Gunning B (2000a) Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology 148: 322-324
51. Reneman L, Booij J, de Bruin K, de Wolff FA, Gunning WB, den Heeten GJ, vd Brink W (2001a) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869
52. Reneman L, Lavalaye J, Booij J, Schmand B, de Wolff FA, vd Brink W, den Heeten GJ, Booij J (2001b) Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethaphetamine (MDMA or "Ecstasy") - preliminary findings. Arch Gen Psychiatry 58: 901-906
53. Reneman L, Majoie CBLM, Schmand B, vd Brink W, den Heeten GJ (2001c) Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) Ecstasy users: preliminary report. Biol Psychiatry 50: 550-554
54. Reneman L, Majoie CBLM, Habraken JBA, den Heeten GJ (2001d) Diffusion and the effects of Ecstasy (MDMA) on the brain in abstinent users: initial observations with diffusion and perfusion MR imaging. Radiology 220: 611-617
55. 123I]β-CIT SPECT in detecting MDMA-induced serotonergic neurotoxicity. Synapse 46: 199-205
56. Reneman L, Majoie CBLM, Flick H, den Heeten GJ (2002b) Reduced N-acetylaspartate levels in the frontal cortex of 3,4- methylenedioxymethaphetamine ("Ecstasy") users - preliminary results. AJNR Am J Neuroradiol 23: 231-237
57. 123I]β-CIT SPECT study. Psychopharmacology 159: 335-340
58. Ricaurte GA, McCann UD (1992b) Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann NY Acad Sci 648: 371-382
59. Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193: 153-163
60. Ricaurte G, Bryan G, Strauss L, Seiden L, Schuster C (1985) Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 229: 986-988
61. Ricaurte GA, DeLanney LE, Irwin I, Langston JW (1988) Toxic effects of MDMA on central serotonergic neurones in the primate: importance of route and frequency of drug administration. Brain Res 446: 165-168
62. Ricaurte GA, Martello AL, Katz JL, Martello MB (1992a) Lasting effects of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in non-human primates: neurochemical observations. J Pharmacol Exp Ther 261: 616-622
63. Ricaurte GA, Yuan J, McCann UD (2000) (+/-)3,4- Methylenedioxymethamphetamine ("Ecstasy")-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42: 5-10
64. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD (2002) Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("ecstasy"). Science 297: 2260-2263
65. Ridley RM, Baker HF, Owen F, Cross AJ, Crow TJ (1982) Behavioural and biochemical effects of chronic amphetamine treatment in the vervet monkey. Psychopharmacology 78: 245-251
66. Ryan LJ, Linder JC, Martone ME, Groves PM (1990) Histological and ultrastructural evidence that D-amphetamine causes degeneration in neostriatum and frontal cortex of rats. Brain Res 518: 67-77
67. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993) Serotonergic recovery after (+/-)3,4-(methylenedioxy) methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264: 1484-1491
68. Scheffel U, Ricaurte GA (1990) Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomograpy ligand? Brain Res 527: 89-95
69. 123/125I]RTI-55, an in vivo label for the serotonin transporter. Synapse 11: 134-139
70. Scheffel U, Szabo Z, Mathews WB, Finley PA, Dannals RF, Ravert HT, Szabo K, Yuan J, Ricaurte GA (1998) In vivo detection of short- and long-term MDMA neurotoxicity - a positron emission tomography study in the living baboon brain. Synapse 29: 183-192
71. Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52: 85-90
72. Schmidt CJ (1987a) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240: 1-7
73. Schmidt CJ, Taylor VL (1987b) Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine. Biochem Pharmacol 36: 4095-4102
74. Schmidt CJ, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124: 175-178
75. Seiden LS, Fischman MW, Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1: 215-219
76. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Fatutsubashi M, Takei N, Mori N (2001) Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158: 1206-1214
77. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999) Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69
78. Shulgin A, Shulgin A (1991) Pihkal: a chemical love story. Transform Press, Berkeley, CA
79. Steele TD, Katz JL, Ricaurte GA (1992) Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res 589: 349-352
80. Steele TD, McCann UD, Ricaurte GA (1994) 3,4- Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. Addiction 89: 539-551
81. Steranka LR (1983) Long-term effects of a priming dose and short-term infusion of amphetamine on striatal dopamine neurones in rats. Eur J Pharmacol 96: 159-163
82. Steranka LR, Sanders-Bush E (1980) Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice. Eur J Pharmacol 65: 439-443
83. Stone DM, Stahl DC, Hanson GR, Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128: 41-48
84. Stone DM, Johnson M, Hanson GR, Gibb JW (1987) A comparison of the neurotoxic potential of methylenedioxyamphetamine (MDA) and its N-methylated and N-ethylated derivatives. Eur J Pharmacol 134: 245-248
85. Strote J, Lee JE, Wechsler H (2002) Increasing MDMA use among college students: results of a national survey. J Adolesc Health 30: 64-72
86. Urenjak J, Williams SR, Gadian DG, Noble M (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981-989
87. 11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18: 419-427
88. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R (1996) Dopamine transporters decrease with age. J Nucl Med 37: 554-559
89. Volkow ND, Chang L, Wang G, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001a) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158: 377-382
90. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001b) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21: 9414-9418
91. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 81: 151-160
92. World Health Organization (2001) WHO Expert Committee on Drug Dependence. Thirty-second report. World Health Organ Tech Rep Ser 903: i-v, pp 1-26
93. Woolverton WL, Cervo L, Johanson CE (1984) Effects of repeated methamphetamine administration on methamphetamine self-adminsitration in rhesus monkeys. Pharmacol Biochem Behav 21: 737-741
94. Zhou FC, Tao-Cheng J, Segu L, Patel T, Wang Y (1998) Serotonin transporters are located on the axons beyond the synaptic junctions: anatomical and functional evidence. Brain Res 805: 241-254